CD19 and B-cell non-Hodgkin lymphoma: Additionally, the authors demonstrated that palliative RT (5 × 4 Gy) followed by CD19 CAR T cells in a patient with B cell lymphoma, bearing a large proportion of CD19- cells, resulted in disease-free local control one year after treatment.